Transforming county market CSO?

Finishingrainbow

On May 26, 2021, AstraZeneca China announced that it has obtained the anti-tumor biopharmaceutical Boyouno (bevacizumab injection) from Boan Biologics, a subsidiary of Luye Pharmaceutical Group, in 21 provinces, cities, and autonomous regions in mainland China.

According to the cooperation content, this cooperation with AstraZeneca is mainly responsible for promoting the expansion of bevacizumab injection to the domestic county market.

In fact, the grassroots county market is an area where AstraZeneca has continued to exert its strength in recent years.

It is worth noting that this cooperation is not the first domestic market promotion right that AstraZeneca won in the first half of this year.

• On February 28, AstraZeneca won the right to promote Junshi Biologics anti-PD-1 monoclonal antibody Tuoyi® (Treprizumab injection) in non-core markets in mainland China, and the subsequent approval for listing The exclusive right to promote urothelial cancer indications nationwide.

  
  

  For these 200 products, some media disassembled them into: 50 self-developed products + 50 first-class new drugs developed in cooperation with China + 50 agent products + 50 diagnostic device products.

  
  

  And this year has not passed halfway, AstraZeneca has frequently made big moves.